Chemotherapy (per cycle)

Chemotherapy remains a cornerstone treatment for multiple myeloma, utilizing cytotoxic drugs to destroy malignant plasma cells or inhibit their proliferation. Typically administered in combination with other therapies, it serves as both induction therapy and for disease control in relapsed/refractory cases.

Targeted Therapy (per cycle)

This systemic treatment uses cytotoxic drugs to target and destroy rapidly dividing myeloma cells throughout the body. While newer therapies have emerged, chemotherapy remains fundamental in induction regimens, stem cell transplant preparation, and palliative care for symptomatic disease.

Immunotherapy (per cycle)

This innovative treatment approach harnesses and enhances the body’s immune system to specifically target and eliminate malignant plasma cells. Immunotherapy has revolutionized myeloma care, offering precision targeting with reduced off-tumor toxicity compared to conventional chemotherapy.

Autologous Stem Cell Transplant

Autologous Stem Cell Treatment remains a cornerstone treatment for eligible myeloma patients, offering deeper remission and prolonged survival when combined with high-dose chemotherapy.

Radiation Therapy (per session)

This precision medicine approach uses specialized drugs to disrupt specific molecular pathways critical for myeloma cell survival and proliferation, offering enhanced efficacy with reduced systemic toxicity compared to traditional chemotherapy.

Supportive Medications (monthly)

This essential component of myeloma management focuses on preventing and managing complications while improving quality of life. Tailored to individual needs, it works synergistically with disease-directed therapies.